Immunovant (IMVT) legal chief sells 1,206 shares in tax “sell to cover”

Rhea-AI Filing Summary

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl reported the disposition of 1,206 shares of common stock in open-market sales on July 8, 2026. According to the company’s description, these sales were executed under a mandatory “sell to cover” arrangement to satisfy tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, and were not discretionary trades.

Insights

Insider-trading analyst

Small, mandated tax-withholding sale with limited signaling value.

Chief Legal Officer Christopher Van Tuyl sold 1,206 Immunovant common shares on July 8, 2026 at weighted-average prices around $39–$40 per share. The transactions are coded as open-market sales but the narrative ties them directly to tax withholding on recently vested restricted stock units.

The footnotes state the company requires a sell to cover to fund taxes on RSU vesting, so the sales do not represent a discretionary portfolio decision. Earlier, on April 1, 2025, he had been granted 50,787 RSUs, of which 3,174 vested on July 1, 2026, creating the tax obligation.

Because the activity is both small in size and mechanically linked to compensation vesting, it typically carries limited informational content about management’s view of the stock, compared with a large, voluntary open-market sale.

Insider Trade Summary

Net Seller: 1,206 shares ($47,702)

Net Sell 2 txns

Insider Van Tuyl Christopher

Role Chief Legal Officer

Sold 1,206 shs ($48K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,143	$39.53	$45K
Sale	Common Stock	63	$39.99	$3K

Holdings After Transaction: Common Stock — 179,454 shares (Direct, null)

Footnotes (1)

1. On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Key Figures

Shares sold: 1,206 shares Weighted-average sale price 1: $39.53 per share Weighted-average sale price 2: $39.99 per share +4 more

7 metrics

Shares sold 1,206 shares Total Immunovant common shares sold by the insider on July 8, 2026

Weighted-average sale price 1 $39.53 per share Weighted-average price for 1,143 shares sold in multiple transactions

Weighted-average sale price 2 $39.99 per share Weighted-average price for 63 shares sold in multiple transactions

RSUs granted 50,787 RSUs Restricted stock units granted on April 1, 2025

RSUs vested 3,174 RSUs Portion of RSUs that vested on July 1, 2026

Price range 1 $38.91–$39.89 per share Range of individual trade prices for one sale block

Price range 2 $39.92–$40.03 per share Range of individual trade prices for the other sale block

Key Terms

restricted stock units, sell to cover, weighted average price

3 terms

restricted stock units financial

"the holder was granted 50,787 restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"tax withholding obligations to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 04:14 PM Accepted by SEC EDGAR 07/10/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What did Immunovant (IMVT) insider Christopher Van Tuyl report in this Form 4?

Chief Legal Officer Christopher Van Tuyl reported selling 1,206 shares of Immunovant common stock on July 8, 2026. The transactions were open-market sales linked to tax withholding on vested restricted stock units.

Why did Immunovant (IMVT) CLO Christopher Van Tuyl sell 1,206 shares?

The 1,206-share sale was executed to cover tax withholding obligations from the July 1, 2026 vesting and settlement of RSUs. The filing states it was a mandated “sell to cover” transaction, not a discretionary trade.

At what prices were the Immunovant (IMVT) shares sold by Christopher Van Tuyl?

One reported weighted-average sale price was $39.53 per share, and another was $39.99 per share. Footnotes note multiple trades within ranges of $38.91–$39.89 and $39.92–$40.03 per share.

How are the RSUs related to this Immunovant (IMVT) insider transaction?

On April 1, 2025, the holder was granted 50,787 restricted stock units, previously reported. Of these, 3,174 RSUs vested on July 1, 2026, triggering the tax obligation that led to the reported sell-to-cover transactions.

Does the Immunovant (IMVT) Form 4 say the insider sale was discretionary?

No. The filing states the sale “does not represent a discretionary transaction” and was mandated by the issuer’s election to satisfy tax withholding via a “sell to cover” transaction following RSU vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Tuyl Christopher

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		S		1,143(1)	D	$39.53(2)	179,454	D
Common Stock	07/08/2026		S		63(1)	D	$39.99(3)	179,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Christopher Van Tuyl	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)